Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue 8, 2001, Pages 389-392

  Holstein, A ^a   Plaschke, A ^a   Egberts, E H ^a  

^a KLINIKUM LIPPE DETMOLD   (Germany)

Author keywords

Diabetes mellitus; HIV; Hyperlipidaemia; Lipodystrophy

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

DIABETES MELLITUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIPODYSTROPHY;

EID: 0035665177     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18990     Document Type: Review

References (22)

1. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
2. Lipodystrophy syndrome in HIV infection: What is it, what causes it and how can it be managed?
3. Mitochondrial toxidity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
4. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors
6. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
7. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
8. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population
9. Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor
10. Lipodystrophies
11. Stoffwechselstörungen und lipodystrophie. Unerwünschte wirkungen der antiretroviralen therapie
12. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
13. Franingham Heart Study: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance
14. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
15. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
16. Public health advisory on protease inhibitors for HIV treatment
17. Declining morbidity and mortality among patients with advanced human immunodeficiecy virus infection
18. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study
19. Hyperlipidemia under therapy with protease inhibitors
20. Diabetes, insulin resistance and dyslipoproteinemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
21. Treatment with protease inhibitor associated with peripheral insulin resistance and impaired oral glucose tolerance in in HIV-1-infected patients
22. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus